Literature DB >> 17718696

Clinical and experimental features of MuSK antibody positive MG in Japan.

K Ohta1, K Shigemoto, A Fujinami, N Maruyama, T Konishi, M Ohta.   

Abstract

We investigated the presence of antibodies (Abs) against muscle-specific tyrosine kinase (MuSK) in Japanese myasthenia gravis (MG) patients. MuSK Abs were found in 23 (27%) of 85 generalized seronegative MG (SNMG) patients but not in any of the ocular MG patients. MuSK Ab-positive patients were characterized as having female dominance (M:F, 5:18), age range at onset 18 to 72 (median 45) years old, and prominent oculobulbar symptoms (100%) with neck (57%) or respiratory (35%) muscle weakness. Limb muscle weakness was comparatively less severe (52%), thymoma absent. Most patients had good responses to simple plasma exchange and steroid therapy. MuSK IgG from all 18 patients was exclusively the IgG 4 subclass and bound mainly with the MuSK Ig 1-2 domain. Serial studies of 12 individuals showed a close correlation between the variation in MuSK Ab titers and MG clinical severity (P = 0.01 by Kruskal-Wallis). MuSK Ab titers were sharply decreased in patients who had a good response to early steroid therapy or simple plasma exchange, but there was no change, or a rapid increase on exacerbation after thymectomy. Measurement of MuSK Ab titers aids in the diagnosis of MG and the monitoring of clinical courses after treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17718696     DOI: 10.1111/j.1468-1331.2007.01870.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

Review 1.  Practical Anatomy of the Neuromuscular Junction in Health and Disease.

Authors:  Hiroshi Nishimune; Kazuhiro Shigemoto
Journal:  Neurol Clin       Date:  2018-05       Impact factor: 3.806

2.  Muscle-specific kinase (MuSK) autoantibodies suppress the MuSK pathway and ACh receptor retention at the mouse neuromuscular junction.

Authors:  Nazanin Ghazanfari; Marco Morsch; Stephen W Reddel; Simon X Liang; William D Phillips
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

Review 3.  The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.

Authors:  Inga Koneczny; Judith Cossins; Angela Vincent
Journal:  J Anat       Date:  2013-03-04       Impact factor: 2.610

Review 4.  Myasthenia gravis induced by autoantibodies against MuSK.

Authors:  K Shigemoto
Journal:  Acta Myol       Date:  2007-12

Review 5.  Anti-IgLON 5 Disease.

Authors:  Anna Heidbreder; Konstanze Philipp
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

6.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

7.  Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.

Authors:  Kenji Otsuka; Mikako Ito; Bisei Ohkawara; Akio Masuda; Yu Kawakami; Ko Sahashi; Hiroshi Nishida; Naoki Mabuchi; Akemi Takano; Andrew G Engel; Kinji Ohno
Journal:  Sci Rep       Date:  2015-09-10       Impact factor: 4.379

8.  Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravis.

Authors:  Nazanin Ghazanfari; Marco Morsch; Nigel Tse; Stephen W Reddel; William D Phillips
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of myasthenia gravis.

Authors:  Sandra George; Silvia Paulick; Ilka Knütter; Nadja Röber; Rico Hiemann; Dirk Roggenbuck; Karsten Conrad; Jan-Heiner Küpper
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.